Tagitanlimab (HBM-9167) is a humanized anti-PD-L1 antibody (IgG1κ type). Tagitanlimab selectively blocks the interaction of PD-L1 and PD-1. Tagitanlimab has the potential to be studied in recurrent or metastatic nasopharyngeal carcinoma (NPC).
References:
[1]. Lu S, et al. Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors. Oncologist. 2019 Feb;24(Suppl 1):S21-S30.
[2]. Kaplon H, et al. Antibodies to watch in 2023. MAbs. 2023 Jan-Dec;15(1):2153410.